©The Author(s) 2026.
World J Gastrointest Pharmacol Ther. Mar 5, 2026; 17(1): 112615
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112615
Published online Mar 5, 2026. doi: 10.4292/wjgpt.v17.i1.112615
Table 3 Use of acid suppressants in special populations
| Treatment | Indication | Dose/frequency | Risk/conditions |
| Renal impairment | |||
| Ranitidine[19] | GERD | 150 mg OD | Risk of toxic reactions: In elderly patients with reduced renal function, in patients with hepatic dysfunction |
| Famotidine[21] | Erosive esophagitis | 20 mg OD or 40 mg every other day | Risk of CNS adverse reactions and QT prolongation in moderate and severe renal impairment |
| GU/DU | |||
| Vonoprazan[63] | Erosive esophagitis | 10/20 mg OD | Not recommended: In severe renal impairment (eGFR < 30 mL/minute), for maintenance of healed erosive esophagitis |
| H. pylori eradication | 20 mg BD | ||
| Hepatic impairment | |||
| Vonoprazan[63] | Erosive esophagitis | 10/20 mg OD | Not recommended for H. pylori eradication in moderate to severe hepatic impairment |
| H. pylori eradication | 20 mg BD | ||
- Citation: Sinha SK, Kochhar R, Rao KS, Yadav D, Ray S, Singh AP, Sethy PK, Mahajan R, Reddy DV, Sharma VM, Kumar A, Mishra A, Jain S, Swami OC, Patil D. Acid peptic disorder compass: An Indian expert consensus on comprehensive management. World J Gastrointest Pharmacol Ther 2026; 17(1): 112615
- URL: https://www.wjgnet.com/2150-5349/full/v17/i1/112615.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v17.i1.112615